A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT06629597 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: YL201
DRUG: Docetaxel
DRUG: Capecitabine
DRUG: Gemcitabine

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.